The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial: A study protocol

BACKGROUND: Dementia among the Japanese aged 65 years or over population is estimated to approach about 700 million cases by 2025, and a corresponding rapid increase in Alzheimer disease (AD) can also be expected. The ballooning number of dementia patients, including AD, is creating major medical an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kainuma, Mosaburo, Funakoshi, Kouta, Ouma, Shinji, Yamashita, Ken-ichiro, Ohara, Tomoyuki, Yoshiiwa, Aoi, Murata, Masayuki, Tsuboi, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
3800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505293/
https://www.ncbi.nlm.nih.gov/pubmed/32957414
http://dx.doi.org/10.1097/MD.0000000000022370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505293/
https://www.ncbi.nlm.nih.gov/pubmed/32957414
http://dx.doi.org/10.1097/MD.0000000000022370

Ejemplares similares